When the 2025 financial year is summarized, it becomes clear that Elexir Pharma's sales continue to climb. During the year, revenue reached SEK 167 million, accompanied by a profit of SEK 19 million. This represents an increase of 24 percent compared to the SEK 135 million in revenue and an operating profit of SEK 15.7 million reported in 2024.
Management sees the increasing volumes without eroding profit margins as a clear indication that the chosen strategy is working exactly as intended in practice.
Closing a record year feels good, of course, but what really pleases me is that we are doing it profitably. We have continued to grow while maintaining a healthy business, which gives us a very good foundation for the future," says Frida Asp, CEO of Elexir Pharma.
Three Factors Behind The Increase
To explain the figures of recent years, management points to three main areas of work that have paved the way for the growth in 2025. The first concerns the design of the products, an area seen as crucial for building a recurring customer base in a segment with many alternatives.
The second area is the relationships with retailers. As the majority of sales occur through external channels, it is a priority to be relevant there. The third pillar is the way of working within the organization, where short decision-making paths and an entrepreneurial spirit have enabled the company to navigate quickly.
By not delaying launches or changes, the company believes they have been able to act faster than many other players in the market.
We have been quick in our decisions and dared to test, which has allowed us to take market share from our competitors," says Frida Asp.
Aiming For A Quarter Of A Billion
In addition to the established goods, new launches have contributed to the increased volumes. The company's newly launched sports series and the HA-PY product, aimed at women, are mentioned as concrete examples where clear target group adaptation and modern communication have worked together to drive interest and purchases.
This direction, where communication revolves around why the customer should shop with them, is something the company plans to continue with.
It is a good example of where we want to go, to become clearer about who we are for and why one should choose us," says Frida Asp.
The plan for 2026 is to scale up the parts of the business model that have proven to work best to create continued growth. The aim is now to reach a turnover of SEK 250 million. The existing market for dietary supplements is growing, but is described by the company as fragmented.
This is considered to create room to take more shares for those who dare to develop their way of working. With profitability secured over the past twelve months, the company is now preparing to take the next step forward.
What we have done well so far is to build a strong foundation. What we are doing now is creating the conditions to be able to grow even faster in the future," concludes Frida Asp.